Biological aspects of chondrosarcoma: leaps and hurdles

Publication date: Available online 22 March 2018
Source:Critical Reviews in Oncology/Hematology
Author(s): Benoîte Mery, Sophie Espenel, Jean-Baptiste Guy, Chloé Rancoule, Alexis Vallard, Marie-Thérèse Aloy, Claire Rodriguez-Lafrasse, Nicolas Magné
Chondrosarcomas are characterized by their chemo- and radioresistance leading to a therapeutic surgical approach which remains the only available treatment with a 10-year survival between 30% and 80% depending on the grade. Non-surgical treatments are under investigation and rely on an accurate biological understanding of drug resistance mechanisms. Novel targeted therapy which represents a new relevant therapeutic approach will open new treatment options by targeting several pathways responsible for processes of proliferation and invasion. Survival pathways such as PI3K, AKT, mTOR and VEGF have been shown to be involved in proliferation of chondrosarcoma cells and antiapoptotic proteins may also play a relevant role. Other proteins such as p53 or COX2 have been identified as potential new targets. This review provides an insight into the biological substantial treatment challenges of CHS and focuses on improving our understanding of CH biology through an overview of major signaling pathways that could represent targets for new therapeutic approaches.



https://ift.tt/2HYqf4m